Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Human Siglec-3 (CD33) Fc Chimera Recombinant Protein

Click to view available options
Quantity:
1 mg
100 μg
Description
It is recommended that the protein be aliquoted for optimal storage. It is recommended that sterile water (953 μL) be added to the vial to prepare a stock solution of 1.05 mg/mL. Concentration is measured by UV.
CD33 is a transmembrane protein of the sialic acid-binding immunoglobulin-like lectin (Siglec) family. It belongs to the immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing molecules able of recruiting protein tyrosine phosphatases SHP-1 and SHP-2 to signal assemblies, and these ITIMs are also used for ubiquitin-mediated removal of the receptor from the cell surface. CD33 is expressed on cells of myelomonocytic lineage, binds sialic acid residues in N- and O-glycans on cell surfaces, and is a therapeutic target for acute myeloid leukemia. Further, CD33 is found on granulocyte and macrophage precursors in the bone marrow, but is not on pluripotent stem cells. CD33 is also expressed on, and is a useful marker for, peripheral monocytes. CD33 is useful for distinguishing myelogenous leukemia cells from lymphoid or erythroid leukemias. Diseases associated with CD43 dysfunction include gallbladder lymphoma and extracutaneous mastocytoma.

Specifications
Specifications
Accession Number | P20138 |
For Use With (Application) | Control |
Format | Lyophilized |
Formulation | PBS with 0.01% mannitol, 0.01% Tween 80, 5-8% trehalose and no preservative; pH 7.4 |
Gene ID (Entrez) | 945 |
Molecular Weight (g/mol) | 53.5 kDa |
Name | Human Siglec-3 (CD33) Fc Chimera |
Purification Method | SDS-PAGE |
Quantity | 100 μg |
Regulatory Status | RUO |
Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction